PropertyValue
?:abstract
  • Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
?:creator
?:doi
  • 10.3201/eid2610.201816
?:doi
?:journal
  • Emerg_Infect_Dis
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/75d53aa47197d76d3485a9553b2e6c7da500d92f.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7510728.xml.json
?:pmcid
?:pmid
?:pmid
  • 32609083.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
?:type
?:year
  • 2020-10-15

Metadata

Anon_0  
expand all